Group 1 - The core point of the article is that XinNuoWei (300765.SZ) announced that its subsidiary, Jushi Biotech, received approval from the National Medical Products Administration for the clinical trial of SYS6023, a HER3-targeted antibody-drug conjugate for use in patients with unresectable locally advanced or metastatic breast cancer [1] Group 2 - SYS6023 utilizes a topoisomerase I inhibitor developed by the company as its payload [1] - The approval allows the company to conduct clinical trials, which are necessary before the drug can be marketed and sold, following further regulatory approval [1] - The drug development process is characterized by high investment, high risk, and long cycles, with potential risks including underperformance in clinical trials, failure to obtain regulatory approval, delays in market launch, or lower-than-expected sales post-launch [1]